Health Care [ 12/12 ] | Biotechnology [ 64/74 ]
NASDAQ | Common Stock
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
It has collaboration and license agreements with F.
Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio.
The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | 0.07 Increased by +125.93% | 0.01 Increased by +600.00% |
| May 1, 24 | 0.37 Increased by +106.31% | -0.07 Increased by +628.57% |
| Feb 28, 24 | 0.47 Increased by +137.90% | 0.01 Increased by +4.60 K% |
| Nov 1, 23 | -0.46 Increased by +84.35% | -1.23 Increased by +62.60% |
| Aug 2, 23 | -0.27 Increased by +89.81% | -1.78 Increased by +84.83% |
| May 2, 23 | -5.86 Decreased by -388.33% | -1.38 Decreased by -324.64% |
| Feb 28, 23 | -1.24 Increased by +12.68% | -1.35 Increased by +8.15% |
| Nov 2, 22 | -2.94 Decreased by -1.45 K% | -1.43 Decreased by -105.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 467.17 M Increased by +40.79% | 33.61 M Increased by +182.10% | Increased by +7.19% Increased by +158.32% |
| Jun 30, 24 | 362.93 M Increased by +38.93% | 6.46 M Increased by +126.98% | Increased by +1.78% Increased by +119.42% |
| Mar 31, 24 | 413.46 M Increased by +63.10% | 36.12 M Increased by +106.99% | Increased by +8.74% Increased by +104.29% |
| Dec 31, 23 | 396.78 M Increased by +53.54% | 45.66 M Increased by +141.79% | Increased by +11.51% Increased by +127.22% |
| Sep 30, 23 | 331.82 M Increased by +44.10% | -40.94 M Increased by +84.12% | Decreased by -12.34% Increased by +88.98% |
| Jun 30, 23 | 261.24 M Increased by +11.89% | -23.94 M Increased by +89.66% | Decreased by -9.16% Increased by +90.76% |
| Mar 31, 23 | 253.50 M Increased by +20.24% | -516.75 M Decreased by -392.03% | Decreased by -203.85% Decreased by -309.21% |
| Dec 31, 22 | 258.43 M Increased by +28.28% | -109.24 M Increased by +10.44% | Decreased by -42.27% Increased by +30.18% |